ACXP News and Press, Acurx Pharmaceuticals Inc. From 04/30/25

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Com...

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase PR Newswire STATEN ISLAND, N.Y. , April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a late-stage biopharmaceutical compa...

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors PR Newswire STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a...

2025-03-18 09:44:50 ET Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Conference Call March 18, 2025, 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President and Chief Executive Officer Conference Call ...

2025-03-18 07:07:24 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals stock sinks on $1.1M direct offering Acurx Pharmaceuticals announces $2.5 million registered direct offering Seeking Alpha’s Quant Rating on Acurx Pharmaceuticals Historical ear...

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , March 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stag...

Gritstone bio Inc. (GRTS) is expected to report for Q4 2024 OneConnect Financial Technology Co. Ltd. American Depositary Shares each representing thirty (OCFT) is expected to report for quarter end 2024-12-31 2seventy bio Inc. (TSVT) is expected to report $-0.2 for Q4 2024 CorMedix In...

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering PR Newswire STATEN ISLAND, N.Y. , March 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical...

2025-03-07 08:12:42 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals announces $2.5 million registered direct offering Seeking Alpha’s Quant Rating on Acurx Pharmaceuticals Historical earnings data for Acurx Pharmaceuticals Financial information ...

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering PR Newswire STATEN ISLAND, N.Y. , March 7, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company dev...